{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-25-000121","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.076504+00:00","generated_at":"2026-05-22T07:22:28.088240+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Emergent BioSolutions Q1 net income surges 656% to $68M; revenue down 26% to $222.2M","bullets":["Total revenues $222.2M, down 26% YoY; driven by 62% drop in NARCAN sales to $45.3M.","Net income $68.0M ($1.19 diluted EPS) vs $9.0M prior year; adjusted EBITDA $77.6M, up 16%.","MCM Products segment revenues $156.6M (+1%), driven by 112% increase in Smallpox MCM to $106.4M.","Board authorized $50M share repurchase through March 2026; reaffirmed FY 2025 revenue guidance $750-$850M.","Recent deals: $20M BioThrax contract option, $16.7M BARDA collaboration, exclusive U.S./Canada rights to KLOXXADO."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-25-000121","json":"https://secwatch.observer/filing/0001367644-25-000121.json","markdown":"https://secwatch.observer/filing/0001367644-25-000121.md","text":"https://secwatch.observer/filing/0001367644-25-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000121/0001367644-25-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000121/ebs-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:22:28.088240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}